HORIZON

📅 Upcoming

🕒 Recent(90d)

News

• Sionna says good-bye to 46% of staffers, including exec
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 5h ago
• Exercise — and echocardiograms — in space protected astronauts’ hearts in study
  If humans journey to Mars in 2035, exercise will be critical to keeping their hearts strong in microgravity.
  stat · 11h ago
• The GOP’s $50 billion rural health fund is coming up short, hospital leaders say
  Hospital leaders were excited about the Rural Health Transformation Fund until they saw the fine print.
  stat · 1d ago
• Andy Plump, architect of Takeda’s R&D overhaul, to retire next year
  Plump joined Takeda during a turbulent period, pushed the company to work more closely with young biotechs and will leave it with what CEO Julie Kim called a “lasting foundation.”
  biopharma_dive · 5d ago
• Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints
  While Novartis’ antibody-oligonucleotide conjugate failed to significantly improve hand function in patients with myotonic dystrophy type 1, the asset nevertheless showed signs of clinical activity…
  biospace · 7d ago
• Novartis’ cholesterol-lowering medicine fails Phase 3, clouding Lp(a) horizons
  The failure of Novartis’ pelacarsen to translate its Lp(a)-lowering effects to clinical benefits “marks a meaningful setback” for other companies taking a similar approach to cardiovascular risk, a…
  biospace · 7d ago
• STAT+: Novartis’ experimental cardiovascular drug fails a pivotal study
  A closely watched cardiovascular drug from Novartis failed in a pivotal study, the company said Friday, a major blow to the firm.
  stat · 10d ago
• Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial
  Novartis’ Ionis-partnered drug designed to lower levels of Lp(a), a known cardiovascular risk factor, failed to reduce patients’ risk of a heart attack, stroke, or other major cardiovascular event…
  fiercebiotech · 10d ago
• Beyond GLP‑1s: The race for next‑gen obesity drugs starts in the preclinical models
  Efficacy plateaus, muscle loss and weight rebound are testing the limits of GLP-1 success, pushing companies toward new mechanisms and multitarget designs to close the gap. But progress depends on…
  biospace · 13d ago
• Inside the Gulf biotech deal model, ahead of RGMBS 2026 in Riyadh
  Sovereign capital, guaranteed offtake, and localization mandates are reshaping how biotech deals get structured in the Gulf, ahead of the Riyadh Global Medical Biotechnology Summit (RGMBS) 2026, 14…
  biospace · 20d ago